PMID- 27153447
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 26
IP  - 1
DP  - 2018 Jan
TI  - HER2 Status in Gastroesophageal Adenocarcinomas: Correlation Between 
      Immunohistochemistry and Fluorescence In Situ Hybridization Methodologies.
PG  - 35-39
LID - 10.1097/PAI.0000000000000382 [doi]
AB  - Semiquantitative immunohistochemistry (IHC) is commonly used in combination with 
      fluorescence in situ hybridization (FISH) to detect HER2 amplification in 
      gastroesophageal adenocarcinomas. Most laboratories apply these tests in a 
      sequential algorithm, using IHC as a frontline test and reserving FISH for 
      IHC-equivocal cases. To gain a better understanding of the concordance of IHC and 
      FISH results at our institution, we identified all gastroesophageal 
      adenocarcinomas at our institution tested for HER2 (n=125). Matched IHC and FISH 
      were available for 116 cases (94%). Cases consisted of adenocarcinoma of the 
      distal esophagus (22%), gastroesophageal junction (24%), stomach (43%), and 
      metastatic sites (12%). A total of 88 cases (70%) were biopsies, whereas 37 cases 
      (30%) were resections. Overall, 15 cases (13%) were HER2 positive (IHC 3+ and/or 
      FISH amplified). A total of 60 cases (52%) were IHC score 0; none of these were 
      HER2 amplified by FISH. A total of 30 cases (26%) were IHC 1+; 5 (17%) of these 
      cases were HER2 amplified by FISH. A total of 20 cases (17%) were IHC 2+; 4 (20%) 
      of these cases were HER2 amplified by FISH. A total of 6 cases were IHC score 3+; 
      all of these were HER2 amplified by FISH. Although there was a high overall 
      concordance between IHC and FISH results (96%), a subset (17%) of IHC-negative 
      cases (score 1+) were HER2 amplified as evaluated by FISH, representing 33% of 
      all HER2 amplified cases. This suggests that the common practice of limited FISH 
      testing to IHC 2+ cases will miss a significant number of HER2 amplified cases.
FAU - Robertson, Scott A
AU  - Robertson SA
AD  - Departments of Pathology.
FAU - Cimino-Mathews, Ashley
AU  - Cimino-Mathews A
AD  - Departments of Pathology.
AD  - Oncology, Johns Hopkins School of Medicine, Baltimore, MD.
FAU - Cornish, Toby C
AU  - Cornish TC
AD  - Departments of Pathology.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*diagnosis/genetics/pathology
MH  - Diagnostic Errors
MH  - Esophagogastric Junction/pathology
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry/*standards
MH  - In Situ Hybridization, Fluorescence/*standards
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Reproducibility of Results
EDAT- 2016/05/07 06:00
MHDA- 2018/12/12 06:00
CRDT- 2016/05/07 06:00
PHST- 2016/05/07 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2016/05/07 06:00 [entrez]
AID - 10.1097/PAI.0000000000000382 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):35-39. doi: 
      10.1097/PAI.0000000000000382.